Reactivation of Hepatitis B.

Chemotherapy or immunosuppressive treatment may reactivate HBV Individuals previously infected with the hepatitis B virus who receive chemotherapy or immunosuppressive treatment could be at risk of reactivating the disease according to a summary of statement from the Emerging Styles Meeting, Reactivation of Hepatitis B, and published in Hepatology, a journal of the American Association for the scholarly research of Liver Diseases. Reactivation of HBV can be fatal and the study authors recommend routine screening of HBV in every patients before the begin of treatment with immunosuppressives or anti-cancer drugs. HBV can be transmitted by contact with body liquids, such as for example blood, from an contaminated individual, causing acute or chronic disease that attacks the liver .

in france

Experts studied 149 people with low quality gliomas, a slow-growing kind of brain tumor, who were treated with temozolomide chemotherapy for up to 30 months. However, in 10 % of the combined group, the size of the mind tumors increased by a lot more than 25 %. Genetic testing was performed in 86 of the participants also. In 42 % of the participants, the gene 1p/19q was missing. Those missing the gene were more likely to react well to the medication. They also had more weeks without the tumor developing than people that have the gene and were less likely to die during the study.